FMP

FMP

Enter

VRNA - Verona Pharma plc

Financial Summary of Verona Pharma plc(VRNA), Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercial

photo-url-https://financialmodelingprep.com/image-stock/VRNA.png

Verona Pharma plc

VRNA

NASDAQ

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

15.91 USD

-0.26 (-1.63%)

About

ceo

Dr. David S. Zaccardelli Pharm.D.

sector

Healthcare

industry

Biotechnology

website

https://www.veronapharma.com

exchange

NASDAQ

Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in...

CIK

0001657312

ISIN

US9250501064

CUSIP

925050106

Address

3 More London Riverside

Phone

44 20 3283 4200

Country

GB

Employee

79

IPO Date

Apr 28, 2017

Summary

CIK

0001657312

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

925050106

ISIN

US9250501064

Country

GB

Price

15.91

Beta

0.41

Volume Avg.

443.31k

Market Cap

1.28B

Shares

-

52-Week

11.83-23.81

DCF

3.46

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-22.1

P/B

-

Website

https://www.veronapharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest VRNA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep